Skip to search formSkip to main contentSkip to account menu

OTSSP167

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Maternal embryonic leucine zipper kinase serves as a poor prognosis marker and therapeutic target in osteosarcoma
Osteosarcoma is the most common primary malignancy of bones and frequently affects young children and adolescents. There are… 
2019
2019
Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma
p21-activated kinase 1 (PAK1) stimulates growth and metastasis in non-small cell lung cancer (NSCLC). Protein kinase C iota (PKC… 
2018
2018
Maternal embryonic leucine zipper kinase inhibitor OTSSP 167 has preclinical activity on multiple myeloma bone disease by
Citation: Joséphine Muller, Arnold Bolomsky, Sophie Dubois, Elodie Duray, Kathrin Stangelberger, Erwan Plougonven, Margaux… 
2018
2018
IPA-3 (PAK1 inhibitor) or OTSSP167 (MELK inhibitor) plus auranofin (PKCι inhibitor), a therapeutic option for EGFR mutant, KRAS mutant and squamous cell non-small cell lung cancer (NSCLC).
e24001Background: p21-activated kinase 1 (PAK1) stimulates growth and metastasis in several types of tumors, including NSCLC… 
2017
2017
Exploring Novel Kinase Targets and Novel Pharmacology for Cancer Therapeutics
Kinases are the largest target class of clinically approved cancer therapeutics. However, these drugs only target a small… 
2015
2015
Designing New Kinase Inhibitor Derivatives as Therapeutics Against Common Complex Diseases: Structural Basis of Microtubule Affinity-Regulating Kinase 4 (MARK4) Inhibition.
Drug development for common complex diseases is in need of new molecular entities and actionable drug targets. MAP/microtubule… 
2015
2015
Maternal Embryonic Leucine Zipper Kinase (MELK): a Novel Marker of Poor Prognosis and Attractive Drug Target in High-Risk Patients with Multiple Myeloma
Background: Despite significant progress in the treatment of multiple myeloma (MM) through the introduction of immunomodulatory… 
2014
2014
The crystal structure of MPK38 in complex with OTSSP167, an orally administrative MELK selective inhibitor.
2013
2013
Abstract LB-300: Development of an orally-administrative MELK (maternal embryonic leucine zipper kinase)-targeting small molecule inhibitor that suppresses the growth of various types of human cancer…
Breast cancer is the most common malignancy among women worldwide. Treatment for breast cancer acting on molecular targets in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)